VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

被引：43
作者：
Carbone, David P. [1 ]
Salmon, J. Stuart [3 ]
Billheimer, Dean [2 ]
Chen, Heidi [1 ]
Sandler, Alan [1 ]
Roder, Heinrich [4 ]
Roder, Joanna [4 ]
Tsypin, Maxim
Herbst, Roy S. [5 ]
Tsao, Anne S. [5 ]
Tran, Hai T. [5 ]
Dang, Thao P. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Carolinas Hematol Oncol Associates, Charlotte, NC USA
[4] Biodesix, Steamboat Springs, CO USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LUNG CANCER | 2010年 / 69卷 / 03期
关键词：
Lung cancer; Erlotinib; Bevacizumab; Serum biomarker; Proteomics; Personalized therapy; ENDOTHELIAL GROWTH-FACTOR; MASS-SPECTROMETRY; CHEMOTHERAPY; COMBINATION; RECURRENT;
D O I：
10.1016/j.lungcan.2009.11.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat (R)) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat (R) could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：337 / 340
页数：4
相关论文
共 50 条
[21]   The Use of Bevacizumab in Non-Small Cell Lung Cancer: An Update [J].
Lauro, Salvatore ;
Onesti, Concetta Elisa ;
Righini, Riccardo ;
Marchetti, Paolo .
ANTICANCER RESEARCH, 2014, 34 (04) :1537-1545
[22]   Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib [J].
Dogan, Izzet ;
Khanmammadov, Nijat ;
Ahmed, Melin Aydan ;
Yildiz, Anil ;
Saip, Pinar ;
Aydiner, Adnan ;
Vatansever, Sezai .
CLINICAL CANCER INVESTIGATION JOURNAL, 2022, 11 (04) :5-9
[23]   Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer [J].
Karaca, Halit ;
Geredeli, Caglayan ;
Kaplan, M. Ali ;
Demirci, Umut ;
Alici, Suleyman ;
Artac, Mehmet ;
Isikdogan, Abdurrahman ;
Benekli, Mustafa ;
Balakan, Ozan ;
Arpaci, Erkan ;
Budakoglu, Burcin ;
Uncu, Dogan ;
Guler, Tunc ;
Berk, Veil ;
Ozkan, Metin .
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (01) :1-6
[24]   Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future Developments [J].
Gridelli, Cesare ;
Maione, Paolo ;
Bareschino, Maria Anna ;
Schettino, Clorinda ;
Sacco, Paola Claudia ;
Ambrosio, Rita ;
Barbato, Valentina ;
Falanga, Marzia ;
Rossi, Antonio .
ANTICANCER RESEARCH, 2010, 30 (04) :1301-1310
[25]   Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib [J].
Guttman-Yassky, Emma ;
Mita, Alain ;
De Jong, Maja ;
Matthews, Lesley ;
McCarthy, Sean ;
Iwata, Kenneth K. ;
Verweij, Jaap ;
Rowinsky, Eric K. ;
Krueger, James G. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) :2010-2019
[26]   Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib [J].
Tsujino, Kazuyuki ;
Kawaguchi, Tomoya ;
Kubo, Akihito ;
Aono, Nana ;
Nakao, Keiko ;
Koh, Yasuhiro ;
Tachibana, Kazunobu ;
Isa, Shun-ichi ;
Takada, Minoru ;
Kurata, Takayasu .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (08) :994-1001
[27]   A PROSPECTIVE COHORT STUDY OF NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH BEVACIZUMAB [J].
Naoki, Katsuhiko ;
Soejima, Kenzo ;
Nagase, Seisuke ;
Kanemura, Toshinori ;
Ohhira, Tatsuo ;
Takeda, Yuichiro ;
Ikeda, Norihiko .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S868-S868
[28]   A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab [J].
Naoki, Katsuhiko ;
Takeda, Yuichiro ;
Soejima, Kenzo ;
Arai, Daisuke ;
Naka, Go ;
Nagase, Seisuke ;
Arirnura, Ken ;
Kanemura, Toshinori ;
Ohhira, Tatsuo ;
Ikeda, Norihiko .
ONCOLOGY LETTERS, 2017, 13 (05) :3285-3290
[29]   BEVACIZUMAB BEYOND PROGRESSION IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY RESULTS OF A PHASE II STUDY [J].
Timmer-Bonte, Johanna N. H. ;
Van den Hurk, Desiree G. M. ;
Dohmen, Miriam A. ;
Smits-Vandergraaf, Chantal A. ;
Van der Drift, Miep .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S1255-S1256
[30]   SYNERGISTIC ANTITUMOR ACTIVITY OF BEVACIZUMAB AND ERLOTINIB IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER XENOGRAFT MODELS [J].
Moriya, Yoichiro ;
Yamamoto, Kaname ;
Yanagisawa, Mieko ;
Yorozu, Keigo ;
Kurasawa, Mitsue ;
Furugaki, Koh ;
Iwai, Toshiki ;
Ishikura, Nobuyuki ;
Harada, Naoki .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S768-S768
12345